By VETTAPHARMA reporter – Derek Roche: Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Foundayo™ (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight with weight-related medical conditions.
Foundayo is indicated for use alongside a reduced-calorie diet and increased physical activity to support weight loss and long-term weight management.
A key differentiator of orforglipron is its dosing flexibility, as it is currently the only GLP-1 pill that can be taken at any time of day without food or water restrictions, addressing a major limitation of earlier oral GLP-1 therapies.
In the ATTAIN-1 clinical trial, adults taking Foundayo achieved an average weight loss of 27 pounds on the highest dose, demonstrating clinically meaningful efficacy in obesity management.
The therapy will be made available through LillyDirect®, with pricing starting at $25 per month with commercial insurance coverage and $149 for self-pay patients, supporting broader patient access.
Regulatory approval was also notable for its speed, with the FDA granting clearance as part of the Commissioner’s National Priority Voucher program, achieving approval 50 days after submission and 294 days ahead of the original PDUFA date of January 20, 2027—marking one of the fastest approvals for a new molecular entity in recent years.
As a small-molecule GLP-1 therapy, orforglipron offers potential advantages in manufacturing scalability and patient convenience, positioning it as a significant advancement in the evolving obesity treatment landscape.
